TLSA Tiziana Life Sciences plc

0  0%
Previous Close 6.79
Price To Book 169.69
Market Cap 92,626,176
Shares 13,646,381
Volume 30
Short Ratio
Av. Daily Volume 3,032

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial initiation announced November 28, 2018.
NASH (healthy human volunteers)
Phase 2a top-line data due July 2019.
Hepatocellular carcinoma (HCC)
Phase 2b trial to be initiated 2H 2019.
Milciclib and Sorafenib (Nexavar)
Hepatocellular carcinoma (HCC)
Phase 1 nasal data due 2H 2019.
NASH (healthy human volunteers)

Latest News

  1. Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
  2. Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform
  3. Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational
  4. Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Clinical Trial with Milciclib in Patients With Advanced Liver Cancer
  5. The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company
  6. Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
  7. Nasdaq Keeps Momentum, Other Indexes Close Lower Tuesday
  8. Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)
  9. Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers
  10. Tiziana Announces Closing of Offering and Resulting Total Voting Rights
  11. Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate $5.79 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing $1.78 million of Debt